Mira Kyivska

Insmed receives FDA Priority Review for MAC lung therapy after stock ends session down 3%

Insmed receives FDA Priority Review for MAC lung therapy after stock ends session down 3%
Insmed stock falls 3% to $120

Insmed said U.S. regulators have granted Priority Review to its supplemental New Drug Application for a lung disease therapy. The stock is down 3% on the day at $120.

INSM price prediction
24H -0.33%
$140.87
48H -0.9%
$140.06
7D -3.24%
$136.75
1M 13.38%
$160.24
3M 7.91%
$152.51
6M 0.44%
$141.95
12M -33.78%
$93.59
Current price: $141.33 -3.2200 2.23%
Closed 11/20
Daily range 140.99 Arrow from to Icon 150.00
Weekly range 118.00 Arrow from to Icon 150.00
Loading...

Highlights

  • The FDA granted Priority Review to Insmed's supplemental New Drug Application for Mycobacterium avium complex lung disease, with an action date of January 28, 2027.
  • Insmed stock is down 3% on the day at $120, with a market value near $28.12 billion and trailing revenue of $1.13 billion.
  • All 91 analysts covering Insmed rate the stock a buy, with a median price target of $197.5, about 64.5% above the current price.

The company said the FDA has granted Priority Review to its supplemental New Drug Application for its Mycobacterium avium complex lung disease therapy. The review carries a target action date of January 28, 2027. All 91 analysts who cover the stock currently rate it a buy.

Bearish setup holds as volatility expands and oversold state limits declines

The latest session saw an intraday range expand well beyond the weekly average, with prices moving between $119.62 and $124.1. Shares of Insmed are trading below the MA-20 and MA-200 but remain above the MA-50, reflecting a split daily structure. The overall move fits within a bearish chart setup. Stoch RSI is in oversold territory, indicating that downside risk is becoming stretched and may limit further declines.

Downside odds dominate as volatility persists and weekly trend stays negative

Traders should watch whether Insmed stock closes above $124.14 or drops below $118.49 to gauge market acceptance of the recent move. The wide spread between $119.62 and $124.1 during the latest session underscores ongoing volatility. Over the next five trading days, the probability of further downside stands at 67%, while the chance of upside is 33%, with price action expected within a $114.41 to $125.58 range. Even so, the past week has brought a sharp move lower without a sustained trend. A close above $124.14 would indicate buyers are gaining traction, while a drop below $118.49 would suggest the move is being rejected. On the weekly chart, the longer-term picture stays negative.

Earlier, analysts noted that Insmed’s bullish momentum was supported by rising commercial prospects and strong institutional interest. The Priority Review announcement introduces a regulatory catalyst to the story, but with the stock now reflecting a bearish daily structure and heightened volatility, traders should monitor $124.14 and $118.49 as the key levels likely to determine short-term direction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.